What is Tesamorelin?

Tesamorelin is a research peptide in the GH Secretagogue class. Synthetic GHRH analog; stimulates endogenous growth-hormone pulsatility. It is studied at per-dose ranges of 1–2 mg / day (7–14 mg weekly), administered daily sc (evening) over cycles of 12 weeks on / 4 off. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

44-amino-acid GHRH analog. FDA-approved for HIV-associated visceral adiposity. Acts on pituitary somatotrophs; preserves physiological GH pulsatility.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Tesamorelin work?

Primary mechanism: Synthetic GHRH analog; stimulates endogenous growth-hormone pulsatility. Research on Tesamorelin implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Tesamorelin remain areas of active investigation; several proposed effects within the GH Secretagogue class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Tesamorelin dosage & protocol

Reference protocol for Tesamorelin (research context only, drawn from published literature):

  • Per dose: 1–2 mg / day
  • Weekly total: 7–14 mg
  • Frequency: Daily SC (evening)
  • Cycle: 12 weeks on / 4 off

Stacking Tesamorelin

Commonly referenced pairing with Tesamorelin: Ipamorelin. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Tesamorelin stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, pregnancy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Tesamorelin — common questions

What is Tesamorelin and what is it used for in research?
Tesamorelin is classified within the GH Secretagogue group. 44-amino-acid GHRH analog. FDA-approved for HIV-associated visceral adiposity. Acts on pituitary somatotrophs; preserves physiological GH pulsatility. Research applications focus on the pathways outlined below. All references on this page describe published research only — Tesamorelin is supplied for in-vitro and laboratory use, not for human consumption.
How does Tesamorelin work?
Primary mechanism: Synthetic GHRH analog; stimulates endogenous growth-hormone pulsatility. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Tesamorelin remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Tesamorelin research dose?
Published research protocols for Tesamorelin describe per-dose ranges of 1–2 mg / day, with a weekly total near 7–14 mg, administered daily sc (evening). Typical cycle: 12 weeks on / 4 off. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Tesamorelin in Thailand?
Tesamorelin is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Tesamorelin be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Primary reference — peer-reviewed mechanism paper.
  2. Clinical trial data (where available).
  3. Pharmacokinetic profile — half-life and metabolism.
  4. Review of receptor binding affinities.